**A key ruling has kept President Trump’s tariffs on multiple countries intact, as the legal battle over these policies is poised to escalate to the Supreme Court.**
**Trump’s Tariff Battles Continue Amid Legal Uncertainty**

**Trump’s Tariff Battles Continue Amid Legal Uncertainty**
**Federal appeals court allows many of Trump’s tariffs to remain in place, complicating international trade relations.**
In a significant ruling, a federal appeals court has temporarily upheld a series of tariffs imposed by President Trump on various trading partners, including China, Canada, and Mexico. This decision has put a hold on an earlier ruling that would have mandated the administration to roll back the tariffs classified as illegal. The court’s decision does not directly address the legal arguments surrounding the tariffs but provides the Trump administration with the opportunity to retain its leverage in ongoing trade negotiations.
With this ruling, Trump retains the capability to enforce many of the tariffs he introduced during his presidency, ensuring that his administration can continue to utilize them as a negotiating tool. He had previously announced reciprocal tariffs on most nations but paused these measures in early April. The court’s maintenance of these tariffs means that existing trade discussions with over a dozen countries are left in a precarious state.
The judicial system has increasingly become a checkpoint for Trump’s executive power. Reports indicate that within the first few months of his second term, courts have rebutted approximately 180 of his initiatives. In related news, a judge has placed a temporary hold on the Trump administration’s controversial ban on international student enrollments at Harvard University. Meanwhile, a Colombian asylum seeker endured three weeks in a U.S. facility after mistakenly crossing into Canada, further highlighting the complexities within the current administration’s immigration policies. Additionally, the Trump administration has canceled a significant contract with Moderna aimed at developing a bird flu vaccine for humans, rounding out a tumultuous week for the White House in matters of both trade and public health.